Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients

Authors Information
Article Notes and Dates
To Cite : Deng H, Wang C, Lai J, Yu S, Xie D, et al. Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients, Hepat Mon. 2016 ;16(9):e40263. doi: 10.5812/hepatmon.40263.
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Liaw YF, Chu CM. Hepatitis B virus infection. The Lancet. 2009; 373(9663): 582-92
  • 2. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 3. Chinese Society of H, Chinese Society of Infectious Diseases CMA. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2011; 32(4): 405-15[PubMed]
  • 4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1)[DOI][PubMed]
  • 5. Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007; 13(47): 6419-24[PubMed]
  • 6. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43(3): 508-14[DOI][PubMed]
  • 7. Fan JG, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008; 23(5): 679-81[DOI][PubMed]
  • 8. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009; 50(1): 204-10[DOI][PubMed]
  • 9. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014; 59(10): 2571-9[DOI][PubMed]
  • 10. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon. 2011; 11(2): 103-6[PubMed]
  • 11. Mao Y, Huang J. Commentary on: Aspartate transaminase to platelet ratio index (APRI): A simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases. Hepat Mon. 2011; 11(5): 376-7[PubMed]
  • 12. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf). 2013; 1(1): 19-26[DOI][PubMed]
  • 13. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012; 19(4): 244-53[DOI][PubMed]
  • 14. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014; 29(7): 1470-6[DOI][PubMed]
  • 15. Ledinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016; 31(4): 848-55[DOI][PubMed]
  • 16. Yuan L, Shao J, Hao M, Li C, Wang G, Wang T, et al. [Correlation between liver hardness testing results obtained by FibroTouch and FibroScan and liver pathological stage]. Zhonghua Gan Zang Bing Za Zhi. 2014; 22(6): 425-9[DOI][PubMed]
  • 17. Ou X, Wang X, Wu X, Kong Y, Duan W, Zhou J, et al. [Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(2): 103-6[DOI][PubMed]
  • 18. Wang R, Ren W, Zhao S, Niu X, Tan P, Du H, et al. [Clinical study on FibroTouch and multi-parameter model for diagnosis of hepatic fibrosis in patients with chronic liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(4): 265-9[DOI][PubMed]
  • 19. Mao CS, B NH, Yin H. The value of FibroTouch fat attenuation parameter in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. Chin J Infect Dis. 2015; 33(6): 339-42
  • 20. Li JB, liu S, Wen B, Gao N, Wang BY. Clinical significance of FibroTouch, ultrasound, and computed tomography in diagnosis of fatty liver disease: a comparative analysis . J Clin Hepatol. 2016; 32(3): 459-62
  • 21. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
  • 22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6): 2005-23[DOI][PubMed]
  • 23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6): 1313-21[DOI][PubMed]
  • 24. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin liver Dis. 2002; 6(2): 335-47
  • 25. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12): 1705-13[PubMed]
  • 26. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014; 39(3): 254-69[DOI][PubMed]
  • 27. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol. 2013; 28(7): 1194-201[DOI][PubMed]
  • 28. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010; 36(11): 1825-35[DOI][PubMed]
  • 29. Macaluso FS, Maida M, Camma C, Cabibbo G, Cabibi D, Alduino R, et al. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. J Hepatol. 2014; 61(3): 523-9[DOI][PubMed]
  • 30. Shen F, Zheng R, Mi Y, Shi J, Chen G, Chen J, et al. [A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver]. Zhonghua Gan Zang Bing Za Zhi. 2014; 22(12): 926-31[DOI][PubMed]
  • 31. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4: 10[DOI][PubMed]
  • 32. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6: 33[DOI][PubMed]
  • 33. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42(7): 503-8[DOI][PubMed]
  • 34. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3): 865-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check